SBIR Phase II: A high throughput microfluidic platform to accelerate biomanufacturing tran — NSF Award to ONECYTE BIOTECHNOLOGIES,
The broader/commercial impact of this Small Business Innovation Research (SBIR) Phase II project is accelerating the manufacturing of and access to newly developed therapeutics and vaccines. To address global health problems, effective and safe new biologics such as therapeutics and vaccines will need to be manufacture
| Award title | SBIR Phase II: A high throughput microfluidic platform to accelerate biomanufacturing tran |
|---|---|
| Award ID | 2309447 |
| Awardee | ONECYTE BIOTECHNOLOGIES, INC. |
| City | WATERTOWN |
| State | MA |
| Amount obligated | $1,186,726 |
| Principal investigator | Konstantinos Tsioris |
| Program | SBIR Phase II |
| Start date | 09/15/2023 |
| Abstract | The broader/commercial impact of this Small Business Innovation Research (SBIR) Phase II project is accelerating the manufacturing of and access to newly developed therapeutics and vaccines. To address global health problems, effective and safe new biologics such as therapeutics and vaccines will need to be manufactured at unprecedented large scales and short times. Accelerating access to new biologics for potentially billions of individuals will be critical for healthcare and the global economy |
| Source | NSF Awards |
$799/mo
Try NSFGrants →